Artelo Biosciences (NASDAQ:ARTL) Releases Earnings Results, Beats Estimates By $0.06 EPS

Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings results on Tuesday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06, Zacks reports.

Artelo Biosciences Price Performance

Shares of NASDAQ ARTL opened at $1.06 on Thursday. Artelo Biosciences has a 1 year low of $1.00 and a 1 year high of $1.75. The firm has a market cap of $3.42 million, a PE ratio of -0.37 and a beta of 1.35. The company has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.28.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ARTL shares. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a research report on Wednesday. EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.